Straw Mushroom

Metadata

Regulatory Status

China

• Widely cultivated and consumed as a food mushroom, particularly in southern China
• Not listed in the Chinese Pharmacopoeia as an official drug
• One of the first mushrooms cultivated in Asia, with documented cultivation since the 18th century
• TCM use as a food for strengthening the spleen and stomach, promoting qi

Southeast Asia

• One of the most important commercially cultivated mushrooms in Thailand, Vietnam, Philippines, Myanmar, and Indonesia
• Available fresh, canned, and dried in virtually all markets
• Major agricultural commodity with economic significance for smallholder farmers
• Low production costs with approximately 45-day cropping duration

United States

• Available primarily in canned form in Asian grocery stores
• Fresh specimens rarely available due to short shelf life
• No FDA GRAS formal assessment
• Not marketed as a dietary supplement

European Union

• Available in canned form; limited fresh availability
• No Novel Food regulatory issue for traditional preparations
• Not widely consumed compared to Asian markets

Japan / Korea

• Available but not among the primary cultivated species in these markets
• No specific pharmaceutical or functional food approval

Conditions & Indications

Primary (Preclinical Evidence)

• Immunomodulation — Fip-vvo protein stimulates maximum proliferation of human peripheral blood lymphocytes at 5 microg/mL; selectively enhances transcription of IL-2, IL-4, IFN-gamma, TNF-alpha, lymphotoxin, and IL-2 receptor, suggesting cytokine-mediated immunomodulation [Source: Hsu et al., 1997]
• Antitumor activity — Volvatoxin A2 causes lysis of tumor cells and inhibits protein biosynthesis in cancer cells; demonstrated selectivity for solid tumors with minimal animal toxicity [Source: Lin et al., 1973; PMC review, 2024]

Secondary (Preclinical)

• Antioxidant activity — Fruiting body extracts demonstrate significant DPPH radical scavenging, FRAP, and metal chelating activity attributed to phenolic compounds, flavonoids, and ergothioneine [Source: Heliyon review, 2024]
• Cardiovascular protection — Nicotinic acid (3-pyridinecarboxylic acid) reduces cardiovascular disease risk markers; polyphenols provide anti-inflammatory vascular protection [Source: PMC review, 2024]
• Antimicrobial — Extracts show activity against various pathogenic bacteria and fungi in vitro [Source: Heliyon review, 2024]

Emerging/Preclinical

• Anti-malarial activity — Reported antimalarial properties in preliminary in vitro screening [Source: Heliyon review, 2024]
• Anti-inflammatory — Polysaccharide fractions suppress pro-inflammatory markers in cell models
• Dendritic cell maturation — Fip-vvo enhances maturation and function of mouse dendritic cells, promoting antigen presentation capacity [Source: Shao et al., 2021]

Mechanism of Action

Primary Mechanisms

1. Fip-vvo immunomodulatory protein activity: Fip-vvo is a 112-amino-acid single polypeptide (15 kDa apparent molecular mass, 12,667 Da calculated) that stimulates lymphocyte proliferation through:

   • Binding to cell surface receptors on T-lymphocytes
   • Selective upregulation of cytokine gene transcription (IL-2, IL-4, IFN-gamma, TNF-alpha, lymphotoxin)
   • Enhanced IL-2 receptor expression, creating positive feedback for T-cell activation
   • Promotion of dendritic cell maturation and antigen-presenting function
   • The mechanism parallels other fungal immunomodulatory proteins (FIPs) from Ganoderma lucidum (LZ-8) and Flammulina velutipes (FIP-fve)

2. Volvatoxin-mediated antitumor mechanism: Volvatoxin A2 is a cytolytic protein that:

   • Forms transmembrane pores in target cell membranes (similar to aerolysin-type pore-forming toxins)
   • Causes lysis of red blood cells and tumor cells in vitro
   • Inhibits mitochondrial respiration in tumor cells
   • Shows selectivity — minimal systemic toxicity in animal studies despite in vitro cytolytic activity
   • Heat-labile: destroyed by cooking, rendering the mushroom safe for consumption

3. Ergothioneine antioxidant protection: Ergothioneine is a potent sulfur-containing amino acid antioxidant that:

   • Accumulates in tissues via the organic cation transporter OCTN1
   • Scavenges hydroxyl radicals and hypochlorous acid
   • Protects mitochondrial DNA from oxidative damage
   • May provide cytoprotection to immune cells under oxidative stress

Secondary Mechanisms

• Nicotinic acid cardiovascular effects: Reduces VLDL and LDL cholesterol through inhibition of hepatic diacylglycerol acyltransferase-2; raises HDL through unclear mechanisms
• Polysaccharide-mediated immunomodulation: Beta-glucans activate innate immune cells through Dectin-1 and complement receptor 3
• Phenolic compound antioxidant activity: Direct radical scavenging and metal ion chelation reducing oxidative stress

Clinical Evidence Summary

Key Preclinical Studies

Evidence Limitations

• No human clinical trials published for any medicinal endpoint
• All medicinal evidence is preclinical (in vitro or animal models)
• Fip-vvo characterization is from a single research group’s foundational work (1997); limited independent replication
• Volvatoxin research is primarily from older studies (1970s-1990s) with limited modern follow-up
• The heat-labile nature of key bioactive proteins (volvatoxin, Fip-vvo) means cooking destroys them, creating a paradox: the food form is safe but loses some bioactive proteins
• Species authentication in older studies may not reflect current taxonomy
• Most research does not differentiate between developmental stages (egg stage vs. mature), though bioactive profiles likely differ

Safety Profile

General Assessment

As the third most widely cultivated mushroom globally, V. volvacea has an extensive safety record as a cooked food. Annual production and consumption across tropical Asia provide massive population-level safety data for culinary use. However, raw or undercooked specimens contain heat-labile volvatoxin, which is cardiotoxic.

Contraindications

• Known allergy to Basidiomycota mushrooms
• Must always be consumed thoroughly cooked — never raw or undercooked
• Caution in individuals with pre-existing cardiac conditions if consuming undercooked preparations

Drug Interactions

No clinically documented drug interactions. The nicotinic acid content is nutritionally relevant but unlikely to reach pharmacological interaction thresholds at dietary doses. Theoretical immunostimulatory interactions with immunosuppressive drugs are possible but undemonstrated.

Side Effects

• As cooked food: Very well-tolerated; no commonly reported adverse effects
• Raw/undercooked: Volvatoxin A1 can cause hemolysis of red blood cells, mitochondrial swelling in liver cells, and potentially cardiac arrest — always cook thoroughly
• Mild GI discomfort possible in sensitive individuals
• Allergic reactions rare

Toxicology

Volvatoxin:

• Volvatoxin A1 is cardiotoxic: causes RBC lysis, mitochondrial damage, inhibition of protein biosynthesis
• Volvatoxin A2 shows antitumor selectivity with minimal animal toxicity
• Both toxins are heat-labile and completely inactivated by thorough cooking (>70 degrees C)

Heavy metal accumulation:

• V. volvacea can bioaccumulate heavy metals (particularly lead) from contaminated substrates
• Cultivation on clean, tested substrates is essential for food safety
• Wild-collected specimens from polluted areas should be avoided

General:

• No specific LD50 data published for the cooked mushroom
• Ames test data not available
• Long history of safe culinary consumption when properly cooked

Look-alike Warning

Young V. volvacea in the “egg” (universal veil) stage can be confused with deadly Amanita species (e.g., A. phalloides, A. verna) that also emerge from egg-like structures. This confusion has caused fatalities among foragers unfamiliar with local toxic species. Commercial cultivation eliminates this risk.

Clinical Dosage

Dietary (Culinary)

• Fresh fruiting body: 100-200 g per serving, always thoroughly cooked
• Available fresh (short shelf life), canned (most common in export markets), and dried
• The “egg” stage (before veil rupture) is most prized culinarily for its firm texture
• Commonly used in stir-fries, soups, and curries in Southeast Asian and southern Chinese cuisine

Research Extract Doses (In Vitro — Not Validated in Humans)

• Fip-vvo: Maximum lymphocyte proliferation at 5 microg/mL in vitro — no human dosage established
• Polysaccharide extracts: Various concentrations used in cell culture studies
• No standardized human supplement dosage established

Quality Considerations

• Freshness is paramount: V. volvacea has a very short shelf life (2-3 days fresh)
• Canned straw mushrooms retain nutritional value but may lose some heat-sensitive bioactives during processing
• Substrate quality directly affects heavy metal content — commercially cultivated on clean straw is preferred
• The “button” or egg stage has different bioactive profiles from fully opened caps

Sources

• Hsu HC, et al. Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea. Biochem J. 1997;323(Pt 2):557-565
• Lin JY, et al. The cytotoxic effects of volvatoxin A2 on Ehrlich ascites tumor cells. Toxicon. 1973;11(3):317-322
• Shao B, et al. The enhancing effect of fungal immunomodulatory protein-Volvariella volvacea (FIP-vvo) on maturation and function of mouse dendritic cells. Life (Basel). 2021;11(6):471
• Bala N, et al. Volvariella volvacea (paddy straw mushroom): A mushroom with exceptional medicinal and nutritional properties. Heliyon. 2024;10(22):e40747
• Chang ST. The world mushroom industry: Trends and technological development. Int J Med Mushrooms. 2006;8(4):297-314
• Jia L, et al. Exploring the nutritional and medicinal properties of Volvariella volvacea: A comprehensive review. Food J. 2025
• Royse DJ, et al. Production of shiitake, nameko, maitake, lion’s mane, and straw mushroom. In: Edible and Medicinal Mushrooms. Wiley; 2017:251-282
• Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002;60(3):258-274

Connections

• Compare with Shiitake — both contain fungal immunomodulatory proteins (FIPs), but shiitake’s lentinan polysaccharide has far more clinical evidence
• Compare with Reishi — Reishi’s LZ-8 protein is structurally related to Fip-vvo; both belong to the FIP protein family with similar immunomodulatory mechanisms
• Compare with Oyster Mushroom — both are widely cultivated edible mushrooms with emerging medicinal interest; oyster mushroom has more clinical evidence for cholesterol reduction
• Compare with Button Mushroom — as the first and third most cultivated mushrooms globally, both have massive safety databases from dietary consumption
• Compare with Maitake — maitake beta-glucans (MD-fraction) have more established immunomodulatory clinical evidence
• The volvatoxin pore-forming mechanism is unique among medicinal mushrooms and represents a distinct class of mushroom-derived antitumor proteins
• Ergothioneine content connects to similar antioxidant profiles in Oyster Mushroom and Shiitake